Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jun 28;5(7):e595.
doi: 10.1097/HS9.0000000000000595. eCollection 2021 Jul.

Survival in Primary Myelofibrosis: A Population-based Analysis in the Netherlands

Stefanie Slot  1 , Avinash G Dinmohamed  1   2   3 , Otto Visser  4 , Peter A W Te Boekhorst  5 , Sonja Zweegman  1
Affiliations

Survival in Primary Myelofibrosis: A Population-based Analysis in the Netherlands

Stefanie Slot et al. Hemasphere. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
RS of patients with primary myelofibrosis in the Netherlands. (A) and (B), RSRs according to the calendar period of diagnosis for the age categories 18–65 y (A) and >65 y (B). The tables below (A) and (B) present the projected 5- and 10-y RSR with 95% CIs. The asterisk indicates the P value for the likelihood ratio test assessing linear trends in 5-y RS from the period 2001–2010 to the period 2011–2018. (C), RS as per the IPSS risk groups, among patients diagnosed during 2014–2018. The table below (C) presents the projected 2- and 5-y RSR with 95% CI. CI = confidence interval; Int = intermediate; IPSS = International Prognostic Scoring System; RS = relative survival; RSR = relative survival rates; Unk = unknown.
Figure 2.
Figure 2.
Primary treatment of patients with primary myelofibrosis in the Netherlands. (A), Information on primary therapy (ie, initial therapy started after diagnosis, including a “wait-and-see policy”) according to age and at diagnosis and calendar period of diagnosis among patients diagnosed during 2001–2018. The absolute number and proportion of patients within a specific age group and period is shown in Supplementary Table S3 (http://links.lww.com/HS/A160). The group of other therapy encompasses immunomodulatory imide drugs, interferon-alpha, and ruxolitinib (as of 2011), among others. Of note, 6 patients with missing information on therapy were not included in this figure. (B), Specific type of primary therapy as per the IPSS risk group in the 2 age groups among patients diagnosed during 2014–2018. The absolute number and proportion of patients within a specific risk and age group is shown in Supplementary Table S5 (http://links.lww.com/HS/A160). The group of other therapy is delineated in Supplementary Table S6 (http://links.lww.com/HS/A160). alloSCT = allogeneic stem cell transplantation; Int = intermediate; IPSS = International Prognostic Scoring System.
See this image and copyright information in PMC

References

    1. Harrison CN, Vannucchi AM, Kiladjian JJ, et al. . Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis. Leukemia. 2016; 30:1701–1707 - PMC - PubMed
    1. Verstovsek S, Mesa RA, Gotlib J, et al. . Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial. J Hematol Oncol. 2017; 10:55. - PMC - PubMed
    1. Cervantes F, Dupriez B, Pereira A, et al. . New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009; 113:2895–2901 - PubMed
    1. Passamonti F, Maffioli M, Cervantes F, et al. . Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts. Blood. 2014; 123:1833–1835 - PubMed
    1. Shallis RM, Wang R, Davidoff A, et al. . Epidemiology of the classical myeloproliferative neoplasms: the four corners of an expansive and complex map. Blood Rev. 2020; 42:100706. - PubMed